retatrutide clinical trial safety Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 retatrutide clinical trial safety data
Pay in 4 interest-free payments of $6.88 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16













![Klow vs Glow Peptide: 5 Key Differences [Comparison 2026]](https://klow-peptide.com/images/content/heroes/klow-vs-glow.jpg)







